A Study of Patients With Dry Mouth and Sticky Saliva During Radiotherapy

Assessing the Safety and Effectiveness of Visco-ease for the Treatment of Radiotherapy Induced Xerostomia in Head and Neck Cancer Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02687087

Enrollment

Registered

2016-02-22

Start date

2016-03-24

Completion date

2017-02-02

Last updated

2017-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Xerostomia

Keywords

Radiotherapy Induced Xerostomia (RIX)

Brief summary

The purpose of this study is to evaluate the clinical safety and effectiveness of Visco-ease dry mouth spray for the treatment of Radiotherapy Induced Xerostomia (RIX) in head and neck cancer patients. A parallel group double blind study design has been selected. The primary outcome is change in GRIX scores from baseline (visit 1) to end of treatment (visit 7). The primary outcome will be compared between Visco-ease and the placebo treatment.

Interventions

DEVICEVisco-ease

19.6 mg/mL of LMS-611

DEVICEPlacebo

Physiological Saline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Subject has provided written informed consent 2. Male or female subjects ≥ 18 years of age 3. Subjects prescribed radiotherapy or chemoradiotherapy as primary treatment for head and neck tumours where one or more parotid glands will receive a significant dose of radiation as judged by the CI or PI during the radiotherapy planning process

Exclusion criteria

1. Subject is pregnant or breastfeeding 2. Subjects with known allergies to egg, soya, or lanolin (sheep's wool grease) based products 3. Subjects with a history of an autoimmune disease with pre-treatment xerostomia (e.g. Sjögren's syndrome) or other underlying systemic illness known to cause xerostomia independent of prior radiation therapy exposure 4. Subjects who have participated in an investigational medicinal product study within 30 days prior to signing consent 5. Any clinically significant disease or condition that may interfere with the study treatment or outcome of the study (at the discretion of the CI or PI) 6. Subjects who are unable to independently complete the questionnaire or diary 7. Subjects who are judged inappropriate for inclusion in the study by the CI or PI 8. Subjects with head and neck cancer who have had surgery to the primary site. Neck dissection alone is not an exclusion

Design outcomes

Primary

Measure	Time frame	Description
Change in GRIX Score	From baseline (Visit 1) to end of treatment (Visit 7, after 6 weeks of treatment)	The primary endpoint will compare change in GRIX scores from baseline to 6-week follow-up between the group treated with Visco-ease and the Placebo group.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026